Inhaled drug developer Alexza Pharmaceuticals has announced the promotions of Edwin S. Kamemoto to Executive VP, R&D and Quality and Lori H. Takahashi to VP, Pharmaceutical R&D and Quality. Both positions are newly created.
Kamemoto joined Alexza in 2006 and was most recently Senior VP, Regulatory Affairs. Takahashi joined Alexza in 2005 and most recently served as Executive Director, Non-Clinical R&D.
Alexza develops inhaled therapies based on its Staccato thermal aerosolization platform, including Adasuve Staccato loxapine, which was approved by the FDA in December 2012 The company is also developing inhaled alprazolam, zaleplon, and fentanyl.
Read the Alexza press release.
